EIRGENIX DEVELOPS AND MANUFACTURES BIOLOGICS
EirGenix is a CDMO to provide high quality and cost-effectiveness service supporting our clients in development, analytical testing, and cGMP manufacturing of biopharmaceuticals from pre-clinical to commercial manufacturing.
2013-12-06
Related the latest news
EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
2021/07/21
HONG HAI/FOXCONN FOUNDER TERRY GUO ANNOUNCES INVESTMENT TO ACCELERATE EIRGENIX’S GLOBAL EXPANSION
2021/04/06
POSITIVE PHASE III CLINICAL RESULTS FOR EIRGENIX'S PROPOSED TRASTUZUMAB BIOSIMILAR
2021/03/23
EIRGENIXは日本市場を拡大するために、日本の会社と長期供給契約の締結について
2021/03/02
VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!
2020/09/26
EIRGENIX ACHIEVES THE THIRD MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
2020/09/11
EIRGENIX RECEIVES 2020 BIOPROCESSING EXCELLENCE IN GREATER CHINA REGION AWARD!
2020/07/07
EIRGENIX ACHIEVES THE SECOND MILESTONE OF ITS BIOSIMILAR TRASTUZUMAB - LICENSING AGREEMENT
2020/03/09
EIRGENIX RECEIVES APPROVAL FROM JAPAN'S PMDA
2020/02/03
EIRGENIX COLLECTS ITS INITIAL SIGNING FEE DAYS BEFORE ITS OFFICIAL IPO
2019/06/27
EIRGENIX INC. ANNOUNCES 3-DAY STOCK OPTION BIDDING AHEAD OF ITS LATE-JUNE IPO
2019/06/10
EIRGENIX HOLDS ITS PRE-IPO PRESS CONFERENCE
2019/05/29
EIRGENIX SIGNS TRASTUZUMAB BIOSIMILAR LICENSE AGREEMENT WITH NOVARTIS SANDOZ
2019/04/30
EIRGENIX AWARDED FOR ITS INNOVATION AT THE NATIONAL INDUSTRIAL INNOVATION AWARDS
2019/04/10
EIRGENIX, INC. WINS BEST BIOPROCESS EXCELLENCE IN TAIWAN AWARD
2019/02/27
EIRGENIX, INC. OFFICIALLY OPENS ITS NEW WORLD-CLASS COMMERCIAL MASS PRODUCTION FACILITY
2019/01/23
EIRGENIX'S PHASE III CLINICAL TRIAL OF EG12014 HAS ENROLLED FIRST PATIENT
2018/10/30
CANCER THERAPEUTIC DRUG EG12014 IS APPROVED FOR PHASE III CLINICAL TRIAL
2018/05/22
EIRGENIX IS AWARD TOP 145 OF THE TECHNOLOGY FAST 500 COMPANIES IN ASIA PACIFIC (APAC)
2018/05/09
EIRGENIX RECEIVED "ASIA'S BEST CMO"
2018/01/31
EIRGENIX RECEIVED THE ACCREDITATION CERTIFICATE OF FOREIGN DRUG MANUFACTURER FROM JAPAN
2017/11/08
EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" BEAM-RAISING CEREMONY
2017/10/19
CANCER THERAPEUTIC DRUG EG12014 PASSED THE DOUBLE-BLINDED PHASE I CLINICAL TRIAL
2017/05/02
EIRGENIX RECEIVED "GRAND WINNER OF BEST BIOPROCESS EXCELLENCE IN TAIWAN"
2017/02/16
EIRGENIX HELD THE WHOLE NEW "PROTEIN DRUG COMMERCIAL PRODUCTION PLANT" GROUNDBREAKING CEREMONY
2016/12/30
2015 TAIWAN BIO-MEDICAL AND NEW AGRICULTURAL INDUSTRY DRAFT COMPETITION AWARDS CEREMONY
2015/09/24
EIRGENIX AND FORMOSA LABORATORIES COLLABORATE TO ESTABLISH A PLATFORM FOR ADC CMC INTEGRATION SERVIC
2014/06/23
EG12014'S PHASE III CLINICAL TRIAL INTERIM RESULTS PUBLISHED AT SAN ANTONIO BREAST CANCER SYMPOSIUM
2021/12/08
BIOLOGICS LICENSE APPLICATION (BLA) SUBMITTED TO U.S FDA FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR
2021/12/18
MARKETING AUTHORIZATION APPLICATION (MAA) SUBMITTED FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR TO EMA
2021/12/21
EIRGENIX ACHIEVES THE FIFTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
2022/01/26
EIRGENIX COMPLETES NEOADJUVANT TREATMENT AND SURGERY FOR LAST PATIENT IN PHASE III CLINICAL TRIAL
2020/11/08
EirGenix Completed Its NTD 5.03 Billion Private Placement on the Fifteenth of October
2021/10/15
EIRGENIX'S REVENUE REACHES A RECORD HIGH IN JUNE
2019/07/10
EirGenix rated top 5% Corporate Governance Evaluation at TPEx after second year of the IPO
2022/05/04
EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
2023/05/01